Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
September 15 2022 - 8:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research and development of new and effective treatments for
central nervous system (CNS) disorders, today announced the
appointment of Dr. Merit Cudkowicz to its Scientific Advisory Board
(“SAB”).
Dr. Cudkowicz is the Chief of Neurology at
Massachusetts General Hospital, Director of the Sean M. Healey
& AMG Center for ALS, and the Julieanne Dorn Professor of
Neurology at Harvard Medical School. A member of the National
Academy of Medicine, Dr. Cudkowicz has been a pioneer in promoting
and devising more efficient methods for the development of new
therapies for people with neurological disorders such as ALS and is
one of the founders and co-directors of the Northeast ALS
(NEALS) Consortium, a group of over 130 clinical sites in the
United States and Canada dedicated to performing collaborative
academic-led clinical trials in ALS. Dr. Cudkowicz is also the
Study Chair and Principal Investigator of the HEALEY ALS Platform
Trial, a perpetual multi-center, multi-regimen clinical trial
evaluating the safety and efficacy of investigational products for
the treatment of ALS.
“Dr. Cudkowicz’s achievements in the research
and treatment of ALS are extraordinary and second to none, and her
collaborative, cross-field methodology has revolutionized ALS
clinical trials. Her knowledge, experience, and forward-thinking
approach will be a huge asset to Pasithea as we advance our mission
of bringing our alpha-5/beta-1 monoclonal antibody to clinical
trials in ALS,” said Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics.
“I am honored that my role with the SAB will
allow me to work closely with Dr. Steinman and the team at Pasithea
on their new program for ALS. Their approach is novel, with
preclinical and human post-mortem data supporting a role for
alpha-5/beta-1 integrin in the pathophysiology of ALS. The
preclinical efficacy data of Pasithea´s monoclonal antibody
targeting alpha-5/beta-1 integrin is very encouraging and we will
work together to bring this drug to clinical trial for people
living with ALS,” stated Dr. Cudkowicz.
Dr. Cudkowicz received the American Academy of
Neurology 2009 Sheila Essay ALS award, the 2017 Forbes Norris Award
from the International MND Alliance, the 2017 Pinnacle Award from
the Boston Chamber of Commerce, and the 2019 Ray Adams American
Neurological Association Award. She received a B.S. in Chemical
Engineering from Massachusetts Institute of Technology, an M.D.
from Harvard Medical School, and a MSc. in Clinical Epidemiology
from Harvard School of Public Health.
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a
biotechnology company focused on the discovery, research and
development of new and effective treatments for central nervous
system (CNS) disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders, including Amyotrophic Lateral Sclerosis
(ALS) and Multiple Sclerosis (MS). Pasithea is also focused on
addressing the needs of patients currently suffering with mental
illness by providing access to IV ketamine infusions both in
clinics and in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024